Eli Lilly stock performed well in Q2, exceeding expectations with revenue and earnings growth

From Nasdaq: 2024-08-14 00:13:04

Eli Lilly (LLY) stock outperformed expectations in Q2, with revenues of $11.3 billion and adjusted earnings of $3.92 per share, surpassing estimates. The stock has surged over 15% since the results were announced, showing a strong performance over the past few years. The company raised its full-year outlook.

Eli Lilly’s Q2 results showed a 36% y-o-y revenue growth, driven by market share gains for key drugs like Mounjaro and Verzenio. Adjusted earnings grew by 86%, with the company expecting strong sales growth for Mounjaro and Verzenio in the future. The company raised its full-year sales and earnings outlook significantly.

Despite strong performance, Eli Lilly stock is appropriately priced, with peers in the pharmaceutical sector also showing positive trends. Comparisons with other companies and Trefis High Quality Portfolio show how Eli Lilly is positioned in the market. The company’s recent success has also reflected in impressive returns over the past few years.



Read more at Nasdaq: What’s Next For Eli Lilly Stock After A Solid Q2?